Edwards Lifesciences Corporation $EW Shares Purchased by Andra AP fonden

Andra AP fonden grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 283.2% during the first quarter, HoldingsChannel.com reports. The fund owned 114,969 shares of the medical research company’s stock after purchasing an additional 84,969 shares during the quarter. Andra AP fonden’s holdings in Edwards Lifesciences were worth $9,207,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its position in Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after purchasing an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after buying an additional 648,870 shares during the period. Sivik Global Healthcare LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $2,984,000. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter worth approximately $803,686,000. Finally, TD Asset Management Inc raised its stake in Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,577 shares of company stock worth $3,855,527 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Truist Financial boosted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Evercore reiterated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Barclays restated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. BTIG Research upped their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Stock Performance

Shares of EW opened at $84.41 on Wednesday. The company’s fifty day moving average is $87.60 and its 200-day moving average is $83.91. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The firm has a market cap of $48.61 billion, a price-to-earnings ratio of 44.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same period in the prior year, the company posted $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.